GW501516 and SR9009 are each a small molecule rather than a peptide.
Same target, different schedules: GW501516 once daily in the trials; SR9009 not established.
| Comparison | GW501516 (Cardarine) Cardarine · GW-501516 | SR9009 (Stenabolic) Stenabolic · SR-9009 |
|---|---|---|
| How it works | How it works This is the compound in this library with the clearest reason not to take it. | How it works SR9009 is not a peptide and not a SARM, though it is sold alongside both. |
| What it is | A discontinued drug whose development stopped over cancer in multiple organs. | A body clock drug sold as a workout replacement, with an oral absorption problem. |
| Status | Research only | Research only |
| Typical dose | 2.5–10 mg per day | 20–30 mg per day |
| How often | Once daily in the trials | Not established |
| Stays active | Nothing published | Nothing published |
| Dose comes from | Clinical trial protocol | Community practice |
| Cycled? | Not established No established range | Not established No established range |
| What it does | ||
| Drug class | PPAR-delta agonist (small molecule) | REV-ERB agonist (small molecule) |
| Used for | Sold for endurance and fat loss. Development was discontinued after animal carcinogenicity findings. | Sold orally for endurance, fat loss and metabolic effects. |
| Receptors hit | — | — |
| Numbers | ||
| Full dose line | 2.5 up to 10 mg per day | Research only |
| Why that cycle | No schedule has been studied for this compound in people. | No schedule has been studied for this compound in people. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | Not disclosed |
| Common vial | — | — |
| Before you start | ||
| Route | By mouth (oral) | By mouth (oral) |
| Do not use if | Anyone, on the basis of the carcinogenicity findings that stopped its development Pregnancy or breastfeeding Any history of cancer Anyone competing in drug-tested sport Anyone who wants established safety data, because none exists for this compound in humans | Pregnancy or breastfeeding Anyone competing in drug-tested sport Anyone who wants established safety data, because none exists for this compound in humans |
What separates them
Proof behind the dose. GW501516 has a dose from a clinical trial protocol. SR9009 has a range that comes from community practice, with no published human study behind it.
What doesn't differ: They are both taken the same way (by mouth) and aimed at the same thing (endurance & fat loss). Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
GW501516 (Cardarine)
- High risk: animal carcinogenicity findings ended its pharmaceutical development.
- Banned in drug-tested sport, and the subject of an unusual public warning from anti-doping authorities.
- Signs of an allergic reaction, including spreading hives, facial or throat swelling, or trouble breathing
- Anything unusual, since there is no known safety profile to compare it against
SR9009 (Stenabolic)
- The effect data comes from injected animals while the product is sold as an oral capsule.
- Banned in drug-tested sport.
- Signs of an allergic reaction, including spreading hives, facial or throat swelling, or trouble breathing
- Anything unusual, since there is no known safety profile to compare it against
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.